<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892019000100002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Leucemia linfoide crónica de células B: revisión de sus aspectos etiopatogénicos, moleculares y pronósticos]]></article-title>
<article-title xml:lang="en"><![CDATA[B-cell chronic lymphoid leukemia: a review of its etiopathogenic, molecular and prognostic aspects]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Triana Marrero]]></surname>
<given-names><![CDATA[Yenisey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marsán Suárez]]></surname>
<given-names><![CDATA[Vianed]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Ballester]]></surname>
<given-names><![CDATA[Amanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Domínguez]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892019000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892019000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892019000100002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La leucemia linfoide crónica (LLC) es una neoplasia maligna que afecta principalmente a pacientes de mediana edad y ancianos. Se caracteriza por la proliferación de linfocitos morfológicamente maduros pero inmunoincompetentes que se acumulan en sangre periférica, médula ósea y tejido linfático. Presenta gran heterogeneidad clínica. Se describen diversos fenotipos, aunque predomina la expansión clonal de células B CD5+CD23+. Los factores pronósticos en la LLC incluyen el subgrupo citogenético, estado mutacional de inmunoglobulina, la expresión de ZAP-70, CD38 y CD49d. El tratamiento se basa en usar modernos algoritmos terapéuticos aprobados, que produzcan mayores respuestas y menores eventos secundarios, en lograr la remisión clínica completa y mejorar la calidad de vida de estos pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Chronic lymphocytic leukemia (CLL) is a malignancy that mainly affects middle-aged and elderly patients. It is characterized by the proliferation of morphologically mature but immunoincompetent lymphocytes that accumulate in blood, bone marrow and lymphatic tissue. It presents great clinical heterogeneity. Several phenotypes are described, although the clonal expansion of CD5 + CD23 + B cells predominates. Prognostic factors include the cytogenetic subgroup, immunoglobulin mutational status, expression of ZAP-70, CD38, and CD49d. The treatment is based on using modern approved therapeutic algorithms that produce greater responses and minor secondary events, to achieve complete clinical remission and to improve the quality of life of these patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[leucemia linfocítica crónica]]></kwd>
<kwd lng="es"><![CDATA[inmunofenotipo]]></kwd>
<kwd lng="es"><![CDATA[factores pronósticos]]></kwd>
<kwd lng="en"><![CDATA[chronic lymphocytic leukemia]]></kwd>
<kwd lng="en"><![CDATA[immunophenotype]]></kwd>
<kwd lng="en"><![CDATA[prognostic factors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias Segura]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[González Valero]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfocítica crónica]]></article-title>
<source><![CDATA[LUX MÉDICA]]></source>
<year>2013</year>
<volume>8</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>29-38</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarmiento]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Scolnik]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Stanganelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución de la leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología]]></article-title>
<source><![CDATA[Medicina (B. Aires)]]></source>
<year>2002</year>
<volume>62</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>305-12</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Puerta]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chacón]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfática crónica B. Diagnóstico, pronóstico y tratamiento]]></article-title>
<source><![CDATA[Actual Med]]></source>
<year>2017</year>
<volume>100</volume>
<numero>800</numero>
<issue>800</issue>
<page-range>52-3</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdespino-Gómez]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfocítica crónica de linfocitos B: un modelo personalizado de valoración clínica y molecular]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>103-21.</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenwald]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alizadeh]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Widhopf]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia]]></article-title>
<source><![CDATA[J Exp Med]]></source>
<year>2001</year>
<volume>194</volume>
<page-range>639-47</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kipps]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoglobulin genes in chronic lymphocytic leukemia]]></article-title>
<source><![CDATA[Blood Cells]]></source>
<year>1993</year>
<volume>19</volume>
<page-range>615-25</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stamatopoulos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antigens in CLL: themes and variations]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2010</year>
<volume>115</volume>
<page-range>3855-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steininger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Widhopf]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Ghia]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Morello]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Vanura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B cell superantigen]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<page-range>2293-301</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puente]]></surname>
<given-names><![CDATA[XS]]></given-names>
</name>
<name>
<surname><![CDATA[Pinyol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quesada]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Conde]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ordóñez]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Villamor]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2011</year>
<volume>475</volume>
<numero>7354</numero>
<issue>7354</issue>
<page-range>101-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woyach]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The B cell receptor signaling pathway as a therapeutic target in CLL]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Byrd]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>120</volume>
<page-range>1175-84</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buggins]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gohil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fishlock]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Patten]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Geyer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2011</year>
<volume>154</volume>
<page-range>216-22</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CCN]]></given-names>
</name>
<name>
<surname><![CDATA[Fecteau]]></surname>
<given-names><![CDATA[J-F]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2013</year>
<volume>110</volume>
<page-range>6127-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suping]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Pathogenesis of Chronic Lymphocytic Leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kipps]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Rev Pathol]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>103-18</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuneo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Cavazzini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Daghia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Med]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>555-64</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villegas-Gracia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linfocitosis monoclonal de células B: una revisión de aspectos generales]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Franco-Alzate]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo-Arbeláez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev CES Med]]></source>
<year>2015</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-38</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rozovski]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Personalized medicine in CLL: Current status and futureperspectives]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hazan-Halevy]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Estrov]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Lett]]></source>
<year>2014</year>
<volume>352</volume>
<page-range>4-14</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muhammad]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Chronic Lymphocytic Leukemia. Medscape 2017]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Dongen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Adriaasen]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunobiology of leukemia. Leucemia]]></source>
<year>2016</year>
<edition>6th ed</edition>
<page-range>83-130</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[WB Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pui]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Behm]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Crist]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>82</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drenon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Flowcytometry: application for the diagnosis and the follow-up of hematological malignancies]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fardel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Fauchet]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amiot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Biol Clin]]></source>
<year>2013</year>
<volume>60</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>663-72</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagnucco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multidimensional flow cytometry immunophenotyping of hematologic malignancy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vanelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gervasi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>2013</year>
<volume>963</volume>
<page-range>313-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandes]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[de Lourdes Chauffaille]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<source><![CDATA[Cytometry B Clin Cytom]]></source>
<year>2014</year>
<volume>86</volume>
<page-range>98-105</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dragovi&#263;]]></surname>
<given-names><![CDATA[IT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Immunophenotyping in Differential Diagnosis of Chronic Lymphocytic Leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kraguljac]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Kne&#382;evi&#263;]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bogdanovi&#263;]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Biljana Mihaljevi&#263;]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bo&#382;i&#263;]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Srp Arh Celok Lek]]></source>
<year>2014</year>
<volume>142</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>197-203</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piedras]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citometría de flujo en el diagnóstico y clasificación de padecimientos hematológicos: leucemias agudas, síndromes linfoproliferativos crónicos y glicoproteínas plaquetarias]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2006</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>53-62</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marom]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Truong]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>123</volume>
<page-range>2783-90</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idelalisib and rituximab in relapsed chronic lymphocytic leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Sharman]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Coutre]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[New Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>997-1007</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howlader]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Noone]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Krapcho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garshell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Altekruse]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How will B-Cell receptor targeted therapies change future cell therapy?]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Byrd]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>123</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1455-60</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mertens]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches?]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Stilgenbauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>869-72</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
